Atea Pharmaceuticals (AVIR) Competitors $3.16 +0.06 (+1.94%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVIR vs. BCYC, AVDL, COLL, SEPN, BCAX, ZYME, GYRE, PSTX, PAHC, and NUVBShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Nuvation Bio Atea Pharmaceuticals (NASDAQ:AVIR) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations. Does the media refer more to AVIR or BCYC? In the previous week, Bicycle Therapeutics had 20 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 23 mentions for Bicycle Therapeutics and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.91 beat Bicycle Therapeutics' score of 0.17 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Is AVIR or BCYC more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Bicycle Therapeutics -450.64%-27.35%-20.81% Do analysts recommend AVIR or BCYC? Atea Pharmaceuticals currently has a consensus price target of $6.88, suggesting a potential upside of 117.72%. Bicycle Therapeutics has a consensus price target of $36.00, suggesting a potential upside of 137.78%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Do institutionals and insiders hold more shares of AVIR or BCYC? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 17.8% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer AVIR or BCYC? Bicycle Therapeutics received 117 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 69.95% of users gave Bicycle Therapeutics an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Bicycle TherapeuticsOutperform Votes13569.95% Underperform Votes5830.05% Which has preferable valuation and earnings, AVIR or BCYC? Atea Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea Pharmaceuticals$351.37M0.76-$135.96M-$2.07-1.53Bicycle Therapeutics$36.90M28.33-$180.66M-$3.29-4.60 Which has more risk and volatility, AVIR or BCYC? Atea Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. SummaryAtea Pharmaceuticals beats Bicycle Therapeutics on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.84M$6.87B$5.20B$9.31BDividend YieldN/A3.06%4.80%4.06%P/E Ratio-1.5310.75128.1117.53Price / Sales0.76287.461,260.62139.54Price / CashN/A56.6541.3637.95Price / Book0.485.394.894.92Net Income-$135.96M$152.04M$119.92M$225.78M7 Day Performance6.76%-4.33%16.64%-1.56%1 Month Performance-0.32%2.79%16.35%6.68%1 Year Performance3.95%17.30%35.47%22.48% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals3.3463 of 5 stars$3.16+1.9%$6.88+117.7%+7.1%$261.84M$351.37M-1.5370BCYCBicycle Therapeutics3.5662 of 5 stars$15.47+12.0%$36.00+132.7%-13.5%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeHigh Trading VolumeAVDLAvadel Pharmaceuticals2.7809 of 5 stars$10.96+5.5%$24.43+122.9%-23.3%$1.06B$138.16M-13.15154Short Interest ↑Positive NewsCOLLCollegium Pharmaceutical3.9712 of 5 stars$30.65+1.9%$42.60+39.0%+4.3%$988.46M$599.25M12.97210News CoveragePositive NewsSEPNSepterna1.7246 of 5 stars$21.81-2.6%$43.67+100.2%N/A$968.36MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.62+0.7%$43.00+144.0%N/A$958.81MN/A0.0032ZYMEZymeworks3.0464 of 5 stars$13.81+9.8%$18.83+36.4%+46.9%$951.23M$76.01M-9.25290Analyst UpgradePositive NewsGYREGyre Therapeutics0.3679 of 5 stars$10.09+4.7%N/A-54.6%$943.63M$105.03M0.0040News CoverageGap UpPSTXPoseida Therapeutics3.7029 of 5 stars$9.52+0.1%$9.50-0.2%+193.2%$930.77M$64.70M-15.10260PAHCPhibro Animal Health4.1953 of 5 stars$22.74+0.3%$19.00-16.4%+97.9%$921.04M$1.05B52.561,940Analyst ForecastNews CoverageNUVBNuvation Bio1.9641 of 5 stars$2.71+3.8%$6.60+143.5%+99.6%$912.11MN/A0.0060 Related Companies and Tools Related Companies Bicycle Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Septerna Alternatives Bicara Therapeutics Alternatives Zymeworks Alternatives Gyre Therapeutics Alternatives Poseida Therapeutics Alternatives Phibro Animal Health Alternatives Nuvation Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVIR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts